AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 261 min read$GRCE

Opaleye Management Inc. purchased $159K of GRCE (indirect holdings)

Opaleye Management Inc. purchased 87,801 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at an average of $1.81 ($1.77–$1.93, $0.16M total) across 2 trades over 2026-10-22 to 2026-10-26.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Oct 26, 2026, 10:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GRCE
Neutral
medium confidence
Mentioned
$GRCE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRCENeutralLow
01

Why it matters

The filing provides the first public disclosure of this insider transaction, offering limited trading insight.

02

Market read

Small insider buy; unlikely to affect market price significantly.

03

What to watch

Potential upcoming clinical data or partnership not disclosed yet.

Relevance 5/10Novelty 4/10Timing: same-day filing

Background

SEC Form 4 filing discloses an indirect ownership purchase by Opaleye Management.

Company-level read

Ticker impact

$GRCENeutralMedium confidence
Context

Form 4 shows Opaleye Management bought 87,801 shares of Grace Therapeutics at $1.8064 avg, $158.6K total.

Expected impact

slight upward pressure as market digests insider buying

Evidence & confidence

Purchase size is modest relative to float; impact limited.

Market effects

Sector

Minimal effect on biotech sector; insider activity typical.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider purchase could be a strategic stake build, but size suggests no strong conviction.

Key entities

  • Company
    Grace Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker GRCE.

  • Investor
    Opaleye Management Inc.

    Institutional investor filing the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRCE insider trading history →

Related articles

AUG 13
$GRCEMed

Grace Therapeutics Announces First Quarter 2027 Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

SEC EDGAR 8-K6 min
JUN 18
$GRCEMed

Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr

SEC EDGAR 8-K4 min